Tagrisso recommended for approval in the EU for unresectable EGFR-mutated lung cancer
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
Total Income in Q2 FY25 stood at Rs. 532.18 crore
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%
Hospital business revenues increase 13.9% to Rs. 1,655 crore
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Subscribe To Our Newsletter & Stay Updated